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Background: In 2006, a county-wide survey of general practitioners (GPs) in the United Kingdom (UK)
identified a reluctance to refer younger men with abnormal prostate specific antigen (PSA) levels.
Younger men have the most to gain from early-detection of prostate cancer (PCa), which remains a
national government priority in the UK and around the world. We sought to assess changes in perception
of abnormal PSA-values amongst UK GPs over the past 10 years.
Materials and methods: A total of 500 self-administered paper questionnaires were distributed to
individually named GPs. One hundred and forty two responded (28.4%), representing a patient popu-
lation of ~600,000. A series of visual analogue questions assessed referral thresholds and understanding
of risk factors related to the development of PCa.
Results: GPs with a median of 23-years experience responded. Although mean PSA threshold for referral
to urology did fall between 2006 and 2016 in both the 45-year (5.42 ng/mL vs. 4.61 ng/mL P ¼ 0.0003) and
55-year (5.81 ng/mL vs. 5.30 ng/mL P ¼ 0.0164) age groups, the median referral values were unchanged.
Significantly, referral thresholds quoted for younger men (<65 years) were considerably higher than
recommended UKmaximum PSA-levels. Using case-based scenarios, practitioners appeared more likely to
refer older men with abnormal PSA values, with GPs reporting an average 56.2% likelihood of referring an
asymptomatic 55-year-old with elevated age-adjusted PSA of 4.6 ng/mL. A total of 95.1% recognised a
family history of PCa to be a potential risk factor but other at-risk categories were not so clearly
understood.
Conclusion: Awareness of abnormal PSA values in UK primary care is improving, but continues to lag
behind the evidence. Strategies to disseminate knowledge of maximum PSA-values to GPs should focus
especially on those for younger patients.
© 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the commonest male cancer across
Europe; one in eight United Kingdom (UK) men will be diagnosedDepartment of Surgery, Uni-
Road, Cambridge, CB2 0QQ,
te Society, Published by Elsevierwith PCa in their lifetime.1 Prostate specific antigen (PSA) testing
was introduced in the 1990s. It has subsequently been used as an ad
hoc diagnostic tool in the UK. The use of PSA and an increasing
awareness of PCa has facilitated a migration towards increased
detection and at an earlier stage,2 but with it has brought concerns
of overdiagnosis and overtreatment.3 It was on this basis that age-
adjusted PSA levels were introduced in 19934 in an attempt to both
highlight younger men at risk of PCa and also to reduce the number
of older men having unnecessary invasive investigations. These














































































Prostate Int 6 (2018) 61e6562past 10 years (Table 1) with the appreciation that a proportion of
men with lower PSA can harbour significant PCa.5,6 It is in younger
men (aged < 60 years) with high-risk disease that the survival
impact of surgical interventionmay bemost valuable.7 Unlike some
European countries, there is no formal PSA screening programme in
the UK, but the National Institute of Health and Clinical Excellence
(NICE) have clear recommendations that informed men over
50 years of age who ask for the test should be offered the test,8 as
well as those with lower urinary tract symptoms or abnormal
digital rectal examination.9 GPs are to refer to urology if the pa-
tient's PSA is above the age-adjusted reference range.10
In 2006 a survey of general practitioners (GPs) throughout
Suffolk, in England, showed a particular reluctance to refer younger
men with abnormal PSA levels.11 It is logical, that younger men
have the most to gain from early diagnosis and curative treatment.
Indeed, the latest evidence suggests a particular advantage to
curative surgical therapy in younger men and those with high-risk
disease.7,12
Given that early diagnosis of malignancy has been a consistent
UK government policy over the past decade,13 and in the context of
this updated evidence, it would be hoped there has been a shift in
GP perception of abnormal PSAs particularly in younger men.
A repeated survey of GPs was performed in 2015/2016 to assess
change in perception of abnormal PSA-values in primary care. We
hypothesised that PSA values for referral would have fallen in line
with the latest maximum age-adjusted PSA values.
2. Materials and methods
Following local study approval, a self-administered question-
naire was developed at the West Suffolk Hospital and Ipswich
Hospital based upon the previously used questionnaire. A series of
visual analogue questions assessed referral behaviour. De-
mographic information, years since qualification, and questions on
exposure to PCa was also sought in addition to questions sur-
rounding brief clinical vignettes. The full questionnaire is available
in the appendices with additional questions added regarding risk
factors for high-risk groups. A total of 500 paper questionnaires
were distributed, by mail, to named GPs in the two hospitals'
combined catchment area. All responses were anonymous to
maintain confidentiality. Individuals inputting datawere blinded to
the providence of each response. Anonymized returns precluded
the chasing of responses. Data was recorded and analysed in MS
Excel 2010 (Microsoft, Washington, USA). Statistical analysis was
performed using StatsDirect (StatsDirect Ltd, Cheshire, UK).
3. Results
The population of the surveyed areawas ~600,000. A total of 142
GPs responded (28.4%) of which 125 (88.0%) contained complete
data. Eighty one (57.0%) responders were male, 103 (72.5%) had
been qualified longer than 15 years. The median estimated number
of men investigated by PSA per GP each month was two (range
0e30), this was unchanged since the 2006 survey. Male GPs re-
ported seeing, on average, an estimated 4.4 men per month for PSATable 1
Recommended maximum PSA values (British Association of Urological
Surgeons).6




70e75 7.2tests, significantly more than female GPs who saw 2.0 (P < 0.0001).
Median estimated number of new patients with PCa seen per year
was six (range 0e36), much higher than the median estimate of
two (range 0e12) in 2006.
Fig. 1 shows the proportion of GPs using each referral threshold
in each of the 2006 and 2016 surveys. The median (range) PSA
thresholds that GPs reported for referral at ages 45, 55, 65, 75, and0
10









Fig 1. Graphs showing the proportion of GPs quoting each PSA value as a referral
threshold, for each age category, in the 2016 and 2006 questionnaire. GP, general
practitioners; PSA, prostate specific antigen.
Thurtle et al / Changes in GP perception of PSA 6385 were 4.5 ng/mL (2.5e10.5), 5.5 ng/mL (2.5e10.5), 5.5 ng/mL
(3.5e10.5), 6.5 ng/mL (4.5e25.5), and 7.5 ng/mL (4.5e25.5)
respectively. These were the same as their respective values in the
2006 survey, except for 65 year-olds, where median PSA fell from
6.5 ng/mL in 2006 to 5.5 ng/mL in 2016. Using mean PSA values,
there were significant reductions in mean PSA values for 45- and
55-year-old men (Table 2). For 65-year-old men there was an in-
crease in reported referral threshold between 2006 and 2016 from
5.34 (ng/mL) to 6.10 (ng/mL) (P ¼ 0.0001). For 85-year-old men
there was also a trend towards higher PSA referral values
(P ¼ 0.058) in the latest survey.
In younger men (aged 45, 55, and 65 years), both median and
mean values are still considerably higher than the recommended
age-adjusted maximum PSA-levels (Table 1).6 However, for 75-
year-olds, the median referral threshold (6.5 ng/mL) was actually
lower than recommended maximum PSA values (7.2 ng/mL).
When GP responses were analysed by GP experience, GPs with
<15 years since qualification referred at lower mean PSA values for
each age category, although this did not reach significance (Table 3).Table 2








45 5.42 (±2.08) 4.61 (±1.72) 0.0003
55 5.81 (±2.04) 5.30 (±1.65) 0.0164
65 5.34 (±1.76) 6.10 (±1.65) 0.0001
75 7.70 (±3.70) 7.34 (±2.79) 0.3211
85 7.66 (±3.50) 8.51 (±4.18) 0.0579
GP, general practitioners; PSA, prostate specific antigen; SD, standard deviation.
Table 3
Mean PSA referral thresholds reported by GPs in 2016, analysed by GP experience.
Patient
age (y)









45 4.55 (±1.52) 4.63 (±1.80) 0.8058
55 5.03 (±1.41) 5.41 (±1.74) 0.1862
65 5.87 (±1.50) 6.20 (±1.71) 0.2784
GP, general practitioners; PSA, prostate specific antigen; SD, standard deviation.
Fig 2. Box-plots demonstrating likelihood of referral for five hypothetical clinical vignettes,
minimum reported values shown). LUTS, lower urinary tract symptoms; PSA, prostate specEven in this subgroup, reported PSA referral thresholds were still
considerably higher than the recommended maximum PSA levels,
particularly for 45 and 65-year-old men.
Five hypothetical brief clinical vignettes were described, as
shown on page 4 of the questionnaire (online supplementary file).
These demonstrated a median 80% likelihood of referring an 85-
year-old with an incidental finding of PSA 18 ng/mL. This
compared with 65% likelihood of referral for a 55-year-old man
with PSA of 4.6 ng/mL, up from 3.6 ng/ml 12 months earlier (Fig. 2).
The mean likelihood for referral of this 55-year-old case was only
56.2%.
A total of 95.1% of respondents recognised a family history of PCa
to be a potential risk factor for PCa. It was found that 43.6% and
27.3% thought a family history of breast cancer, or ovarian cancer
was a potential risk factor respectively and 67.9% and 10.9% of re-
spondents respectively thought smoking and lead exposure were
risk factors. These questions were not asked in 2006.
4. Discussion
4.1. Summary
This study demonstrates that GPs still individually see relatively
few men per month for PSA testing. Despite this, the recognition of
abnormal PSA values in younger men <55 years has improved over
the past decade. However, this still lags behind accepted referral
thresholds and actually worsened for 65-year-old men. There still
appears to be a preponderance for better recognition and better
referral trends for older men with abnormal PSA values in general
practice, compared with younger men, both when assessed using
the estimated referral thresholds and hypothetical clinical sce-
narios. This is paradoxical as the evidence for positive impact of
earlier detection is stronger for younger men.
4.2. Strengths and limitations
This study surveyed GPs representing a large patient population,
in amixed urban and rural catchment which is likely to be typical of
UK primary care. The reassessment, within the same geographical
region allows for changes in perceptions to be assessed within a
similar cohort. These data may be generalizable to other
nonscreened populations, with similar healthcare systems to thewith age and PSA levels (ng/mL) indicated (median, interquartile range, maximum and
ific antigen.
Prostate Int 6 (2018) 61e6564UK, but will not be relevant to countries with formal screening
programmes.
The overall response ratewas relatively low, whichmay produce
a selection bias. As responses were anonymized we did not attempt
a second trawl of responses. As such it is possible we may have
captured those GPs that are most engaged or interested in urology.
The clinical vignettes usedwithin the surveywere deliberately brief
and lacked background information that GPs would ordinarily take
into account. Many GPs would not act upon a single PSA value but
may appropriately repeat PSA tests or assess trends. As with any
survey, there is the potential for difference between reported, and
actual referral behaviour and our findings should be correlated
with actual referral practice.
4.3. Comparison with existing literature
Our clinical vignettes suggest an ongoing preponderance to
refer older menwith abnormal PSAs, compared with younger men.
This mirrors a finding of differences in PSA-testing from a 2011
study in six UK cities which found that only 1.4% of men aged
45e49 years were tested, compared with 11.3% in men aged
75e79 years.14 There has been very little research into GP aware-
ness of abnormal PSA values or referral patterns.
Other studies have focussed on PSA testing behaviours amongst
GPs and demonstrated considerable variability in PSA testing, even
prior to assessing PSA interpretation. A study in 2015 found that
GPs with low tolerance levels for ambiguity, or high anxiety
regarding adverse outcomes, were more likely to perform inci-
dental PSA tests.15 A separate study in 2015 amongst New Zealand
GPs found PSA testing to be related to a GP's approach to over- and
underdiagnosis of prostate cancer.16 Elsewhere, geographical and
socioeconomic differences in rates of PSA-testing have been
reported.14
In 2006, a GP survey, performed in Northern Ireland, found that
only 49% of responders were aware of national guidelines related to
PSA. They also found that male GPs, who had attended post-
graduate urology teaching were more likely to request PSA tests,
and that GPs with >21 years of experience requested the most
tests.17
Putting our results in the context of this literature, not only is
there an ongoing reluctance to refer younger men, this may well be
within a group that are already 'under-tested' by PSA initially. In our
data, GPs with less experience, appear to have a better appreciation
of PSA referral thresholds. Yet, it appears these GPs may not be the
practitioners performing the majority of PSA tests.
The improvement and reduction of PSA referral thresholds in
patients younger than 55 years should be applauded. The potential
superiority of GPs with less experience, may also suggest an
improving pattern over time. However, there remains some dis-
tance between reported GP behaviour and accepted guideline
referral values.
In terms of potential risk factors, GPs were very good at recog-
nising the importance of family history of PCa (95.1%). Indeed, be-
tween 5% and 10% of PCa has been shown to have an inherited
component18 with the relative-risk increasing with number of first
degree relatives affected. Recognition of the importance of family
history of breast or ovarian cancer was lower. The BRCA1 and
BRCA2 genes have been implicated19,20 in PCa such that family
history of breast or ovarian cancer should be regarded as a potential
risk. Very limited evidence of dietary risk factors exist; however,
there may be a degree of protection offered by dietary intake of
lycopenes, and an increased PCa risk associated with obesity.21
There is no convincing evidence of association between lead
exposure or smoking and PCa, which 10.6% and 66.9% of re-
spondents respectively thought was the case.5. Conclusion
Awareness of abnormal PSA values in primary care, particularly
in younger patients, is still lagging behind the evidence and latest
guidelines. Strategies to disseminate knowledge of maximum PSA-
values to GPs should focus on those for younger patients. Post-
graduate teaching on urology may be an effective mechanism of
change. Educational campaigns could remind practitioners that
current UK national guidelines require only a single PSAvalue above
the ‘age-specific reference range’ to make a urology referral.10
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